Most founders of physical-product companies believe the hard part is the idea. Steven Capuano, the founder of SpinalTechUSA and the creator behind the Spinalocity line of spinal-health and rehabilitation tools, has spent years arguing the opposite. By the time a product reaches a customer, he says, the decisions that determine whether the business survives have already been made on a factory floor, in a tooling quote, and in a supplier contract that nobody outside the company will ever read.
“You do not feel your manufacturing choices on launch day,” Capuano said. “You feel them eighteen months later, when you are trying to lower your price, or fill a big order, or fix a defect, and you realize every option you have is expensive because of a decision you made before you sold a single unit.”
Tooling Is a Commitment, Not a Purchase
For companies that make a physical object, tooling is the set of molds, dies, and fixtures used to produce parts at volume. Capuano describes it as the single most underestimated line item a new product company faces. Cheap tooling lowers the upfront cost and quietly raises the cost of every unit that follows. It wears faster, holds looser tolerances, and produces more scrap. Expensive tooling does the reverse, but it ties up cash a young company often does not have.
His rule is to match the tooling to the demand a founder can actually defend with orders, not the demand they hope for. “People buy tooling for the company they imagine they will be in three years,” he said. “Then the three years do not go the way the spreadsheet said, and they are stuck paying for capacity they never used. I would rather re-tool once because we grew than carry the weight of a guess that did not come true.”
The Domestic Versus Overseas Question Is Really a Speed Question
Capuano is direct about the trade-off that consumes new founders: making a product domestically or sourcing it abroad. The conversation usually centers on unit cost, and he thinks that framing misses the point. The real variable, in his experience, is how fast a company can react when something goes wrong.
Overseas production can cut the cost of a part, sometimes sharply. It also lengthens the distance between a problem and a fix. A tolerance drifts, a material substitution slips through, a container sits in a port, and a company that sells a health-related product is suddenly explaining a delay or a quality issue it cannot quickly correct. “The cheaper unit is not cheaper if it costs you a season,” Capuano said. “For a rehabilitation product, trust is the whole business. You cannot rebuild trust at the speed a slow supply chain breaks it.”
His approach has been to keep the parts that define safety, fit, and quality close enough to control, and to source commodity components where distance carries less risk. The point is not patriotism or thrift. It is keeping the company’s ability to respond inside its own hands for the things that matter most.
Minimum Order Quantities Decide Your Cash Flow for You
Suppliers price in volume, and the minimum order quantity, or MOQ, is where a founder’s ambition collides with a founder’s bank balance. A low per-unit price almost always requires committing to a large run. Capuano warns that this is how product companies end up cash-poor while sitting on a warehouse full of inventory.
“Inventory looks like an asset until you need the money,” he said. “Then it looks like the floor it is sitting on.” He counsels founders to treat the first production run as a test of demand rather than an act of faith, even when a larger run lowers the unit cost on paper. The savings are real. They are also frozen the moment the boxes arrive and stay frozen until the units sell.
Quality Control Is a System, Not a Final Step
The last lesson Capuano returns to is that quality cannot be inspected into a product at the end of the line. It has to be built into the relationship with whoever makes it. He has seen founders treat their contract manufacturer as a vendor to be squeezed, then act surprised when corners get cut on the parts the customer cannot see.
For a company whose products touch the body and carry a health claim, he argues, the manufacturer is closer to a partner than a supplier. Specifications, tolerances, materials, and testing have to be written down, agreed to, and checked, because the cost of a failure is not a refund. It is a customer who no longer believes the brand. “The market does not separate your idea from your execution,” Capuano said. “They just hold the product. If the product is right, you earned the right to keep selling. If it is wrong, the idea never gets a second hearing.”
That is the throughline in how Capuano talks about building a product company. The visible parts, the marketing and the launch, get the attention. The invisible parts, the tooling and the sourcing and the order sizes, decide whether the visible parts ever get a chance to matter.
